Form 10-KT - Transition reports [Rule 13a-10 or 15d-10]:
SEC Accession No. 0001628280-17-011941
Filing Date
2017-11-30
Accepted
2017-11-30 16:49:33
Documents
80
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10-KT a093017rasna10-kproject.htm 10-KT 1998363
2 EXHIBIT 21 a09302017rasnaexhibit21.htm EX-21 1501
3 EXHIBIT 24 a09302017rasnaexhibit24.htm EX-24 32951
4 EXHIBIT 31.1 a09302017rasnaexhibit311.htm EX-31.1 14123
5 EXHIBIT 31.2 a09302017rasnaexhibit312.htm EX-31.2 14077
6 EXHIBIT 32.1 a09302017rasnaexhibit321.htm EX-32.1 5282
7 EXHIBIT 32.2 a09302017rasnaexhibit322.htm EX-32.2 5588
  Complete submission text file 0001628280-17-011941.txt   7999554

Data Files

Seq Description Document Type Size
8 XBRL INSTANCE DOCUMENT rasp-20170930.xml EX-101.INS 1693819
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rasp-20170930.xsd EX-101.SCH 53337
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rasp-20170930_cal.xml EX-101.CAL 58323
11 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rasp-20170930_def.xml EX-101.DEF 214330
12 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rasp-20170930_lab.xml EX-101.LAB 654253
13 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rasp-20170930_pre.xml EX-101.PRE 392711
Mailing Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170 646-396-4087
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

EIN.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0929
Type: 10-KT | Act: 34 | File No.: 333-191083 | Film No.: 171231712
SIC: 2834 Pharmaceutical Preparations